Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bibrocathol is a bismuth-containing antiseptic and astringent compound used topically in ophthalmology. It is primarily indicated for the treatment of chronic blepharitis (inflammation of the eyelid margins) and non-infected corneal injuries. The drug works by coagulating proteins on the surface of the mucous membranes and skin, which creates a protective layer and reduces inflammation. Its antiseptic properties help prevent secondary bacterial infections without the use of antibiotics. It is commonly formulated as a 2% eye ointment and has been marketed for several decades, particularly in European markets like Germany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bibrocathol.